Subgroup | No. of studies | OS HR (95Â % CI)d | Weight (%) | Heterogeneity within subgroup | ||
---|---|---|---|---|---|---|
Criteria | Characteristics | I 2 (%) | p value | |||
Experimental drug | Azacitidinea | 3 | 0.67 (0.56, 0.79) | 48.3 | 0 | 0.38 |
Decitabine | 2 | 0.86 (0.73, 1.02) | 51.7 | 0 | 0.85 | |
Subgroup difference | p = 0.04* | |||||
Cytogenetics riskb | Poor risk | 3 | 0.75 (0.56, 1.00) | 43.9 | 26 | 0.26 |
Intermediate risk | 3 | 0.78 (0.40, 1.52) | 37.0 | 65 | 0.06 | |
Good risk | 2 | 0.63 (0.42, 0.93) | 19.0 | 0 | 0.64 | |
Subgroup difference | p = 0.75 | |||||
BM blast countc | More than 30Â % | 2 | 0.79 (0.68, 0.92) | 48.9 | 0 | 0.32 |
Less than 30Â % | 3 | 0.82 (0.57, 1.18) | 51.1 | 74 | 0.02 | |
Subgroup difference | p = 0.85 | |||||
Conventional care regimens | BSC only | 2 | 0.76 (0.53, 1.10) | 28.4 | 44 | 0.18 |
BSC and CTxe | 3 | 0.73 (0.60, 0.90) | 71.6 | 53 | 0.12 | |
Subgroup difference | p = 0.85 |